Nuclear Medicine
<ѻý class="page-description">More in Nuclear Medicine
Findings support PSMA PET in the preoperative workflow of intermediate- and high-risk tumors
But it may be able to deliver net carbon benefits, at least in radiology
Median OS of 15.5 months, PFS of 7.9 months with Ac-225-PSMA in heavily treated patients
Study shows twice as many locally advanced patients upstaged with PET-CT vs conventional staging
Impressive 3-year invasive DFS seen with adaptive response strategy using FDG-PET
All but one patient had a PSA decline after a fractionated dose of 225Ac-J591
Randomized study finds no meaningful difference in events of abnormalities between groups
Small increase in median PFS when combined with second-line chemotherapy
No overall risk increase in large meta-analysis, but higher risk seen for thyroid cancer
Increase in negative predictive value and improved sensitivity versus MRI alone
PSMA-directed agent improved overall survival by median 4 months
Post-jab radiotracer uptake "could prompt unnecessary biopsies and treatments"
Early trial shows improved PFS, response rates versus cabazitaxel
